Global Oncology Clinical Trials Market

Oncology Clinical Trials Comprehensive Study by Design (Observational Studies, Treatment Studies), Phase (Phase I, Phase II, Phase III), Cancer (Lung Cancer, Breast Cancer, Thyroid Cancer, Leukemia, Liver Cancer, Skin Cancer, Lymphoma, Others) Players and Region - Global Market Outlook to 2027

Oncology Clinical Trials Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Oncology Clinical Trials
Oncology trials are often small, single-arm, open-label early-phase studies that assess surrogate end points. Trials in other branches of medicine do not share this inclination toward less reliable designs. The proportion of small, single-arm studies does not significantly differ between cancer types, and there is only a weak correlation between the quantity of trials for a particular cancer type and relative incidence or mortality. This is true despite the fact that treatment options and survival vary widely between cancer types. Drug clinical trials are typically broken down by phase. Phase I, II, and III trials are frequently necessary for the FDA to decide whether to approve a medicine for Clinical trials advance through four phases to test a treatment, find the applicable lozenge, and look for side effects. However, after the first three phases, experimenters find a medicine or other intervention to be safe and effective usage.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


Oncology clinical trial markets are extremely competitive. The market's intense competition is significantly influenced by the swift uptake of cutting-edge medical technologies. Major businesses frequently engage in mergers and acquisitions, as well as new product launches and collaborations, to maintain market share and broaden the product line. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Oncology Clinical Trials market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

IQVIA (United States), PAREXEL International Corporation (United States), Pharmaceutical Product Development, LLC; (United States), Charles River Laboratory (United States), Syneos Health (United States), Medpace (United States), Novotech (Australia), Pivotal (United States) and Haymarket Media, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Oncology Clinical Trials market by and Region.



On the basis of geography, the market of Oncology Clinical Trials has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Design, the sub-segment i.e. Observational Studies will boost the Oncology Clinical Trials market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Phase, the sub-segment i.e. Phase I will boost the Oncology Clinical Trials market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cancer, the sub-segment i.e. Lung Cancer will boost the Oncology Clinical Trials market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
Merck Sharp & Dohme Corp. began a phase II clinical research in March 2021 to examine the security and effectiveness of fixed-dose co-formulated pembrolizumab/quavonlimab (MK-1308A) combined with lenvatinib in hepatocellular cancer patients (HCC).
Results from a phase II study of three oral targeted medicines for chronic lymphocytic leukaemia (CLL) revealed that patients experienced profound remissions following a short course of therapy, according to Haymarket Media, Inc. in 2020., and A phase III clinical trial to evaluate the effectiveness and safety of alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy for patients with HER2-positive advanced breast cancer began in 2020 at Novartis AG.
When a clinical trial is approved to start by the U.S. Food and Drug Administration (FDA), scientists investigate a possible therapy's efficacy and safety in lab settings and on animals. If these studies produce encouraging findings, the FDA approves the intervention's human testing.

Market Drivers
  • Increasing Innovation in the Field Of Oncology
  • Growing Patient of Lungs Cancer

Opportunities
  • Number of People Diagnosed With Cancer Is Expected To Rise Multi-Fold

Restraints
  • Inappropriate Selection of Clinical Trial Candidates and Error in Clinical Trial Design

Challenges
  • Inefficient Clinical Trial Design for Oncology


About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Design
  • Observational Studies
  • Treatment Studies

By Phase
  • Phase I
  • Phase II
  • Phase III

By Cancer
  • Lung Cancer
  • Breast Cancer
  • Thyroid Cancer
  • Leukemia
  • Liver Cancer
  • Skin Cancer
  • Lymphoma
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Innovation in the Field Of Oncology
      • 3.2.2. Growing Patient of Lungs Cancer
    • 3.3. Market Challenges
      • 3.3.1. Inefficient Clinical Trial Design for Oncology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oncology Clinical Trials, by Design, Phase, Cancer and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Oncology Clinical Trials (Value)
      • 5.2.1. Global Oncology Clinical Trials by: Design (Value)
        • 5.2.1.1. Observational Studies
        • 5.2.1.2. Treatment Studies
      • 5.2.2. Global Oncology Clinical Trials by: Phase (Value)
        • 5.2.2.1. Phase I
        • 5.2.2.2. Phase II
        • 5.2.2.3. Phase III
      • 5.2.3. Global Oncology Clinical Trials by: Cancer (Value)
        • 5.2.3.1. Lung Cancer
        • 5.2.3.2. Breast Cancer
        • 5.2.3.3. Thyroid Cancer
        • 5.2.3.4. Leukemia
        • 5.2.3.5. Liver Cancer
        • 5.2.3.6. Skin Cancer
        • 5.2.3.7. Lymphoma
        • 5.2.3.8. Others
      • 5.2.4. Global Oncology Clinical Trials Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Oncology Clinical Trials: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. IQVIA (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PAREXEL International Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pharmaceutical Product Development, LLC; (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Charles River Laboratory (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Syneos Health (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medpace (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novotech (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pivotal (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Haymarket Media, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Oncology Clinical Trials Sale, by Design, Phase, Cancer and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Oncology Clinical Trials (Value)
      • 7.2.1. Global Oncology Clinical Trials by: Design (Value)
        • 7.2.1.1. Observational Studies
        • 7.2.1.2. Treatment Studies
      • 7.2.2. Global Oncology Clinical Trials by: Phase (Value)
        • 7.2.2.1. Phase I
        • 7.2.2.2. Phase II
        • 7.2.2.3. Phase III
      • 7.2.3. Global Oncology Clinical Trials by: Cancer (Value)
        • 7.2.3.1. Lung Cancer
        • 7.2.3.2. Breast Cancer
        • 7.2.3.3. Thyroid Cancer
        • 7.2.3.4. Leukemia
        • 7.2.3.5. Liver Cancer
        • 7.2.3.6. Skin Cancer
        • 7.2.3.7. Lymphoma
        • 7.2.3.8. Others
      • 7.2.4. Global Oncology Clinical Trials Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oncology Clinical Trials: by Design(USD Million)
  • Table 2. Oncology Clinical Trials Observational Studies , by Region USD Million (2016-2021)
  • Table 3. Oncology Clinical Trials Treatment Studies , by Region USD Million (2016-2021)
  • Table 4. Oncology Clinical Trials: by Phase(USD Million)
  • Table 5. Oncology Clinical Trials Phase I , by Region USD Million (2016-2021)
  • Table 6. Oncology Clinical Trials Phase II , by Region USD Million (2016-2021)
  • Table 7. Oncology Clinical Trials Phase III , by Region USD Million (2016-2021)
  • Table 8. Oncology Clinical Trials: by Cancer(USD Million)
  • Table 9. Oncology Clinical Trials Lung Cancer , by Region USD Million (2016-2021)
  • Table 10. Oncology Clinical Trials Breast Cancer , by Region USD Million (2016-2021)
  • Table 11. Oncology Clinical Trials Thyroid Cancer , by Region USD Million (2016-2021)
  • Table 12. Oncology Clinical Trials Leukemia , by Region USD Million (2016-2021)
  • Table 13. Oncology Clinical Trials Liver Cancer , by Region USD Million (2016-2021)
  • Table 14. Oncology Clinical Trials Skin Cancer , by Region USD Million (2016-2021)
  • Table 15. Oncology Clinical Trials Lymphoma , by Region USD Million (2016-2021)
  • Table 16. Oncology Clinical Trials Others , by Region USD Million (2016-2021)
  • Table 17. South America Oncology Clinical Trials, by Country USD Million (2016-2021)
  • Table 18. South America Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 19. South America Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 20. South America Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 21. Brazil Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 22. Brazil Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 23. Brazil Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 24. Argentina Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 25. Argentina Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 26. Argentina Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 27. Rest of South America Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 28. Rest of South America Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 29. Rest of South America Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 30. Asia Pacific Oncology Clinical Trials, by Country USD Million (2016-2021)
  • Table 31. Asia Pacific Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 32. Asia Pacific Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 33. Asia Pacific Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 34. China Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 35. China Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 36. China Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 37. Japan Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 38. Japan Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 39. Japan Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 40. India Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 41. India Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 42. India Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 43. South Korea Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 44. South Korea Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 45. South Korea Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 46. Taiwan Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 47. Taiwan Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 48. Taiwan Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 49. Australia Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 50. Australia Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 51. Australia Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 55. Europe Oncology Clinical Trials, by Country USD Million (2016-2021)
  • Table 56. Europe Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 57. Europe Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 58. Europe Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 59. Germany Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 60. Germany Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 61. Germany Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 62. France Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 63. France Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 64. France Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 65. Italy Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 66. Italy Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 67. Italy Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 68. United Kingdom Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 69. United Kingdom Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 70. United Kingdom Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 71. Netherlands Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 72. Netherlands Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 73. Netherlands Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 74. Rest of Europe Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 75. Rest of Europe Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 76. Rest of Europe Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 77. MEA Oncology Clinical Trials, by Country USD Million (2016-2021)
  • Table 78. MEA Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 79. MEA Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 80. MEA Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 81. Middle East Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 82. Middle East Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 83. Middle East Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 84. Africa Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 85. Africa Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 86. Africa Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 87. North America Oncology Clinical Trials, by Country USD Million (2016-2021)
  • Table 88. North America Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 89. North America Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 90. North America Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 91. United States Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 92. United States Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 93. United States Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 94. Canada Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 95. Canada Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 96. Canada Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 97. Mexico Oncology Clinical Trials, by Design USD Million (2016-2021)
  • Table 98. Mexico Oncology Clinical Trials, by Phase USD Million (2016-2021)
  • Table 99. Mexico Oncology Clinical Trials, by Cancer USD Million (2016-2021)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Oncology Clinical Trials: by Design(USD Million)
  • Table 110. Oncology Clinical Trials Observational Studies , by Region USD Million (2022-2027)
  • Table 111. Oncology Clinical Trials Treatment Studies , by Region USD Million (2022-2027)
  • Table 112. Oncology Clinical Trials: by Phase(USD Million)
  • Table 113. Oncology Clinical Trials Phase I , by Region USD Million (2022-2027)
  • Table 114. Oncology Clinical Trials Phase II , by Region USD Million (2022-2027)
  • Table 115. Oncology Clinical Trials Phase III , by Region USD Million (2022-2027)
  • Table 116. Oncology Clinical Trials: by Cancer(USD Million)
  • Table 117. Oncology Clinical Trials Lung Cancer , by Region USD Million (2022-2027)
  • Table 118. Oncology Clinical Trials Breast Cancer , by Region USD Million (2022-2027)
  • Table 119. Oncology Clinical Trials Thyroid Cancer , by Region USD Million (2022-2027)
  • Table 120. Oncology Clinical Trials Leukemia , by Region USD Million (2022-2027)
  • Table 121. Oncology Clinical Trials Liver Cancer , by Region USD Million (2022-2027)
  • Table 122. Oncology Clinical Trials Skin Cancer , by Region USD Million (2022-2027)
  • Table 123. Oncology Clinical Trials Lymphoma , by Region USD Million (2022-2027)
  • Table 124. Oncology Clinical Trials Others , by Region USD Million (2022-2027)
  • Table 125. South America Oncology Clinical Trials, by Country USD Million (2022-2027)
  • Table 126. South America Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 127. South America Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 128. South America Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 129. Brazil Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 130. Brazil Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 131. Brazil Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 132. Argentina Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 133. Argentina Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 134. Argentina Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 135. Rest of South America Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 136. Rest of South America Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 137. Rest of South America Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 138. Asia Pacific Oncology Clinical Trials, by Country USD Million (2022-2027)
  • Table 139. Asia Pacific Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 140. Asia Pacific Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 141. Asia Pacific Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 142. China Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 143. China Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 144. China Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 145. Japan Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 146. Japan Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 147. Japan Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 148. India Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 149. India Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 150. India Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 151. South Korea Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 152. South Korea Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 153. South Korea Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 154. Taiwan Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 155. Taiwan Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 156. Taiwan Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 157. Australia Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 158. Australia Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 159. Australia Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 160. Rest of Asia-Pacific Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 161. Rest of Asia-Pacific Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 162. Rest of Asia-Pacific Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 163. Europe Oncology Clinical Trials, by Country USD Million (2022-2027)
  • Table 164. Europe Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 165. Europe Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 166. Europe Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 167. Germany Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 168. Germany Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 169. Germany Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 170. France Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 171. France Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 172. France Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 173. Italy Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 174. Italy Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 175. Italy Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 176. United Kingdom Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 177. United Kingdom Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 178. United Kingdom Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 179. Netherlands Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 180. Netherlands Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 181. Netherlands Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 182. Rest of Europe Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 183. Rest of Europe Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 184. Rest of Europe Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 185. MEA Oncology Clinical Trials, by Country USD Million (2022-2027)
  • Table 186. MEA Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 187. MEA Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 188. MEA Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 189. Middle East Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 190. Middle East Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 191. Middle East Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 192. Africa Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 193. Africa Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 194. Africa Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 195. North America Oncology Clinical Trials, by Country USD Million (2022-2027)
  • Table 196. North America Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 197. North America Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 198. North America Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 199. United States Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 200. United States Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 201. United States Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 202. Canada Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 203. Canada Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 204. Canada Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 205. Mexico Oncology Clinical Trials, by Design USD Million (2022-2027)
  • Table 206. Mexico Oncology Clinical Trials, by Phase USD Million (2022-2027)
  • Table 207. Mexico Oncology Clinical Trials, by Cancer USD Million (2022-2027)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oncology Clinical Trials: by Design USD Million (2016-2021)
  • Figure 5. Global Oncology Clinical Trials: by Phase USD Million (2016-2021)
  • Figure 6. Global Oncology Clinical Trials: by Cancer USD Million (2016-2021)
  • Figure 7. South America Oncology Clinical Trials Share (%), by Country
  • Figure 8. Asia Pacific Oncology Clinical Trials Share (%), by Country
  • Figure 9. Europe Oncology Clinical Trials Share (%), by Country
  • Figure 10. MEA Oncology Clinical Trials Share (%), by Country
  • Figure 11. North America Oncology Clinical Trials Share (%), by Country
  • Figure 12. Global Oncology Clinical Trials share by Players 2021 (%)
  • Figure 13. Global Oncology Clinical Trials share by Players (Top 3) 2021(%)
  • Figure 14. Global Oncology Clinical Trials share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 17. IQVIA (United States) Revenue: by Geography 2021
  • Figure 18. PAREXEL International Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. PAREXEL International Corporation (United States) Revenue: by Geography 2021
  • Figure 20. Pharmaceutical Product Development, LLC; (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pharmaceutical Product Development, LLC; (United States) Revenue: by Geography 2021
  • Figure 22. Charles River Laboratory (United States) Revenue, Net Income and Gross profit
  • Figure 23. Charles River Laboratory (United States) Revenue: by Geography 2021
  • Figure 24. Syneos Health (United States) Revenue, Net Income and Gross profit
  • Figure 25. Syneos Health (United States) Revenue: by Geography 2021
  • Figure 26. Medpace (United States) Revenue, Net Income and Gross profit
  • Figure 27. Medpace (United States) Revenue: by Geography 2021
  • Figure 28. Novotech (Australia) Revenue, Net Income and Gross profit
  • Figure 29. Novotech (Australia) Revenue: by Geography 2021
  • Figure 30. Pivotal (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pivotal (United States) Revenue: by Geography 2021
  • Figure 32. Haymarket Media, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Haymarket Media, Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Global Oncology Clinical Trials: by Design USD Million (2022-2027)
  • Figure 35. Global Oncology Clinical Trials: by Phase USD Million (2022-2027)
  • Figure 36. Global Oncology Clinical Trials: by Cancer USD Million (2022-2027)
  • Figure 37. South America Oncology Clinical Trials Share (%), by Country
  • Figure 38. Asia Pacific Oncology Clinical Trials Share (%), by Country
  • Figure 39. Europe Oncology Clinical Trials Share (%), by Country
  • Figure 40. MEA Oncology Clinical Trials Share (%), by Country
  • Figure 41. North America Oncology Clinical Trials Share (%), by Country
List of companies from research coverage that are profiled in the study
  • IQVIA (United States)
  • PAREXEL International Corporation (United States)
  • Pharmaceutical Product Development, LLC; (United States)
  • Charles River Laboratory (United States)
  • Syneos Health (United States)
  • Medpace (United States)
  • Novotech (Australia)
  • Pivotal (United States)
  • Haymarket Media, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 207 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oncology Clinical Trials Market Quantitative research analysis
Global Oncology Clinical Trials Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as IQVIA (United States), PAREXEL International Corporation (United States), Pharmaceutical Product Development, LLC; (United States), Charles River Laboratory (United States), Syneos Health (United States), Medpace (United States), Novotech (Australia), Pivotal (United States) and Haymarket Media, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Oncology Clinical Trials market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Oncology Clinical Trials Market Report?

Have a Query? Click Here

Other Related Reports

Birth Centers Comprehensive Study by Type (Hospital Associated Birth Center, Freestanding Birth Center), Services (Conditions & Consultations (Breastfeeding Consultations, Childbirth Education Classe...
$ 3800